Reneuron Share Discussion Threads

[philh75] 02/10/2019 07:15

Great RNS!

[mirabeau] 02/10/2019 07:12

I don't hold here but If recent price action is not insider trading then I'm a wombat.

[rayrac] 02/10/2019 07:06

Does it martin?!

[martinfrench] 01/10/2019 15:49

and looking at the chart a slight retrace back to 250 seems likely before we move up again.

[martinfrench] 01/10/2019 15:36

Think people just know how Rene's price history has worked, based on results and expect the same.

Add to that very illiquid and trades mean something and you get price rises.

Not rocket science

[eggy6198] 01/10/2019 15:14

Honestly its just undervavled and me know it isnt bad news as they said they would tell us. If this hits it means we more likely have a product in a couple of years. And then its billions not millions the mcap

[dickbush] 01/10/2019 15:12

From 200p to 270p in four trading days. Looks like a leak of something good.

[small crow] 01/10/2019 14:32

If a successful antibiotic on the market is worth around $1 billion, I suspect (and hope) this is probably worth more, but some bridges to cross first, so also hope to continue increasing my stake.

[cf456] 01/10/2019 14:20

"#RENE cohort 2a results leaked ? If they are as positive as trial 1 then this company is worth minimum £150m (£5/share)......"

[small crow] 01/10/2019 14:07

Definitely breakout.

[red army] 01/10/2019 12:23

martinfrench

Within 12 months target

[bg23] 01/10/2019 08:46

given the number of shares in issue, a price target of £6 would give a market capitalisation of £180m

on the back of positive results/announcements on either or both the current clinical trials, I'd think a £180m market cap a lowly outcome.

personally, I'd be thinking that licencing deals and royalty payments for just the RP could be worth north of a £500m valuation......... I cannot imagine the likes of Bausch & Lomb would let Rene slip out of its greasy little fingers for such a paltry amount if the results are as positive as initially announced and commercially attainable ?

[martinfrench] 30/9/2019 21:34

It's about 2 weeks today for presentation, give or take few days. Conference starts on weekend I think.....

[dickbush] 30/9/2019 21:29

Given good data in the next couple of weeks from the RP trial, and then no news from the stroke trial before 2021, perhaps Woodford will be looking for a buyer after the RP trial results. Getting rid of a substantial part of his holding would certainly help the share price.

Eyes down looking for those results.

[martinfrench] 30/9/2019 21:12

Eventual ?

What time frame ?

[red army] 30/9/2019 19:27

My eventual target is £6

[small crow] 30/9/2019 18:46

Good. Let's hope we get another dose of the verticals this week.

[red army] 30/9/2019 17:34

Yes a close above 240p confirms that.

[small crow] 30/9/2019 17:01

Have we broken out yet?

[dickbush] 30/9/2019 15:56

stewart25

Safety always a vital consideration, but please see

Pisces II trial

"Modified Rankin Scale (mRS): Response rates (>1 point improvement from baseline) were measured in 35% of subjects at 12 months post-CTX treatment on the mRS, a 7 point, clinician-reported global measure of disability and dependence upon others in carrying out activities of daily living, A one point improvement in mRS is proven to be clinically meaningful for patients, both in terms of quality of life and healthcare resources needed to care for them. Subgroup analysis showed subjects with NIHSS UL score <4 at baseline an even higher response rate of 50% on the mRS at 12 months post-treatment." (patients with some residual arm movement in the affected arm at baseline).

The next trial (Pisces III/Phase 2b) will include only people who have residual arm movement in the affected arm.

[jensonbensonjohnson] 27/9/2019 20:59

Yep, still here Martin. Proper old skool. Still waiting for way over £10 per share.